Prospects for miR-21 as a Target in the Treatment of Lung Diseases.

Yan Ding, Yapeng Hou, Yanhong Liu, Xiaoyong Xie, Yong Cui, Hongguang Nie

Current pharmaceutical design 2021

filter terms:

MicroRNA (miRNA/miR) is a class of small evolutionarily conserved non-coding RNA, which can inhibit the target gene expression at the post-transcriptional level and serve as significant roles in cell differentiation, proliferation, migration and apoptosis. Of note, the aberrant miR-21 has been involved in the generation and development of multiple lung diseases, and identified as a candidate of biomarker, therapeutic target, or indicator of prognosis. MiR-21 relieves acute lung injury via depressing the PTEN/Foxo1-TLR4/NF-κB signaling cascade, whereas promotes lung cancer cell growth, metastasis, and chemo/radio-resistance by decreasing the expression of PTEN and PDCD4 and promoting the PI3K/AKT transduction. The purpose of this review is to elucidate the potential mechanisms of miR-21 associated lung diseases, with an emphasis on its dual regulating effects, which will trigger novel paradigms in molecular therapy. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Citation

Yan Ding, Yapeng Hou, Yanhong Liu, Xiaoyong Xie, Yong Cui, Hongguang Nie. Prospects for miR-21 as a Target in the Treatment of Lung Diseases. Current pharmaceutical design. 2021;27(3):415-422